Overview
"AtheroChem is tackling the number one killer of adults in industrialized countries. Cardiovascular disease must be more aggressively treated. Patients need to have the same urgency in seeking treatments as they do when diagnosed with other life-threatening diseases such as cancer. We are at the forefront of developing novel molecules to prevent and regress atherosclerotic plaque. Our molecules target an unexploited cellular mechanism and we have already shown beneficial effects in animal models."
Perry M. Kim, PhD
Chief Operating Officer
Our Goal is to build upon our innovative scientific research, which has led us to discover and develop novel compounds that modulate an unexploited enzymatic cellular target in the reverse cholesterol transport pathway.
Our Business Model is to maintain a lean and responsive company capable of adjusting to the external demands of the biopharmaceutical industry, while at the same time driving our research and development efforts on a “real-time” basis as our discovery and development efforts permit.
AtheroChem Inc. is privately held.